Results 231 to 240 of about 7,144,441 (302)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Antibiotic Prophylaxis Strategies and Surgical Site Infections in Colorectal Surgery: A Systematic Review and Network Meta-Analysis.

open access: yesJAMA Netw Open
Motaghi S   +11 more
europepmc   +1 more source

The broad societal value of pembrolizumab for women's cancer in Canada. [PDF]

open access: yesFuture Oncol
Brook E   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy